{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:45:29Z","timestamp":1788342329593,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>High expression levels of human epidermal growth factor receptor 2 (HER2) have been associated with poor prognosis in patients with pancreatic adenocarcinoma (PDAC). However, HER2-targeting immunotherapies have been unsuccessful to date. Here we increase the breadth, potency, and duration of anti-PDAC HER2-specific CAR T-cell\u00a0(HER2.CART) activity with an oncolytic adeno-immunotherapy that produces cytokine, immune checkpoint blockade, and a safety switch (CAd<jats:italic>Trio<\/jats:italic>). Combination treatment with CAd<jats:italic>Trio<\/jats:italic> and HER2.CARTs cured tumors in two PDAC xenograft models and produced durable tumor responses in humanized mice. Modifications to the tumor immune microenvironment contributed to the antitumor activity of our combination immunotherapy, as intratumoral CAd<jats:italic>Trio<\/jats:italic> treatment induced chemotaxis to enable HER2.CART migration to the tumor site. Using an advanced PDAC model in humanized mice, we found that local CAd<jats:italic>Trio<\/jats:italic> treatment of primary tumor stimulated systemic host immune responses that repolarized distant tumor microenvironments, improving HER2.CART anti-tumor activity. Overall, our data demonstrate that CAd<jats:italic>Trio<\/jats:italic> and HER2.CARTs provide complementary activities to eradicate metastatic PDAC and may represent a promising co-operative therapy for PDAC patients.<\/jats:p>","DOI":"10.1038\/s42003-021-01914-8","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T13:04:20Z","timestamp":1616159060000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors"],"prefix":"10.1038","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9642-3926","authenticated-orcid":false,"given":"Amanda","family":"Rosewell Shaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline E.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Way-Champ","family":"Mah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary K.","family":"McKenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Dysthe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngrock","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Parihar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm K.","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4086-4199","authenticated-orcid":false,"given":"Masataka","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"key":"1914_CR1","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","volume":"103","author":"J Ferlay","year":"2018","unstructured":"Ferlay, J. et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur. J. Cancer 103, 356\u2013387 (2018).","journal-title":"Eur. J. Cancer"},{"key":"1914_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41586-020-1970-0","volume":"578","author":"C Calabrese","year":"2020","unstructured":"Calabrese, C. et al. Genomic basis for RNA alterations in cancer. Nature 578, 129\u2013136 (2020).","journal-title":"Nature"},{"key":"1914_CR3","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.3389\/fimmu.2018.01878","volume":"9","author":"D Kabacaoglu","year":"2018","unstructured":"Kabacaoglu, D., Ciecielski, K. J., Ruess, D. A. & Algul, H. Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: current limitations and future options. Front. Immunol. 9, 1878 (2018).","journal-title":"Front. Immunol."},{"key":"1914_CR4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","volume":"18","author":"K Harrington","year":"2019","unstructured":"Harrington, K., Freeman, D. J., Kelly, B., Harper, J. & Soria, J. C. Optimizing oncolytic virotherapy in cancer treatment. Nat. Rev. Drug Discov. 18, 689\u2013706 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1914_CR5","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1586\/14737140.2015.1115725","volume":"15","author":"KJ Harrington","year":"2015","unstructured":"Harrington, K. J. et al. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. Expert Rev. Anticancer Ther. 15, 1389\u20131403 (2015).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"1914_CR6","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/mt.2016.66","volume":"24","author":"AM Noonan","year":"2016","unstructured":"Noonan, A. M. et al. Randomized phase 2 Trial of the oncolytic virus pelareorep (reolysin) in upfront treatment of metastatic pancreatic adenocarcinoma. Mol. Ther. 24, 1150\u20131158 (2016).","journal-title":"Mol. Ther."},{"key":"1914_CR7","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","volume":"27","author":"AR Haas","year":"2019","unstructured":"Haas, A. R. et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. Mol. Ther. 27, 1919\u20131929 (2019).","journal-title":"Mol. Ther."},{"key":"1914_CR8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/PAI.0b013e31828dc392","volume":"22","author":"K Aumayr","year":"2014","unstructured":"Aumayr, K. et al. HER2 gene amplification and protein expression in pancreatic ductal adenocarcinomas. Appl. Immunohistochem. Mol. Morphol. 22, 146\u2013152 (2014).","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"1914_CR9","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/bjc.2012.18","volume":"106","author":"J Harder","year":"2012","unstructured":"Harder, J. et al. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Br. J. Cancer 106, 1033\u20131038 (2012).","journal-title":"Br. J. Cancer"},{"key":"1914_CR10","doi-asserted-by":"publisher","first-page":"14008","DOI":"10.1038\/mto.2014.8","volume":"1","author":"L Farzad","year":"2014","unstructured":"Farzad, L. et al. Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy. Mol. Ther. Oncolytics 1, 14008 (2014).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1914_CR11","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","volume":"33","author":"N Ahmed","year":"2015","unstructured":"Ahmed, N. et al. Human Epidermal Growth Factor Receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J. Clin. Oncol. 33, 1688\u20131696 (2015).","journal-title":"J. Clin. Oncol."},{"key":"1914_CR12","doi-asserted-by":"crossref","unstructured":"Ahmed, N., et al. HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol. 3, 1094\u20131101 (2017).","DOI":"10.1001\/jamaoncol.2017.0184"},{"key":"1914_CR13","doi-asserted-by":"crossref","unstructured":"Tanoue, K., et al. Armed oncolytic adenovirus expressing PD-L1 mini-body enhances anti-tumor effects of chimeric antigen receptor T-cells in solid tumors. Cancer Res. 77, 2040\u20132051 (2017).","DOI":"10.1158\/0008-5472.CAN-16-1577"},{"key":"1914_CR14","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1016\/j.ymthe.2017.09.010","volume":"25","author":"A Rosewell Shaw","year":"2017","unstructured":"Rosewell Shaw, A. et al. Adenovirotherapy delivering cytokine and checkpoint inhibitor augments CAR T cells against metastatic head and neck cancer. Mol. Ther. 25, 2440\u20132451 (2017).","journal-title":"Mol. Ther."},{"key":"1914_CR15","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.ymthe.2020.02.016","volume":"28","author":"CE Porter","year":"2020","unstructured":"Porter, C. E. et al. Oncolytic adenovirus armed with BiTE, cytokine, and checkpoint inhibitor enables CAR T cells to control the growth of heterogeneous tumors. Mol. Ther. 28, 1251\u20131262 (2020).","journal-title":"Mol. Ther."},{"key":"1914_CR16","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1080\/21645515.2017.1412896","volume":"14","author":"RM Conry","year":"2018","unstructured":"Conry, R. M., Westbrook, B., McKee, S. & Norwood, T. G. Talimogene laherparepvec: first in class oncolytic virotherapy. Hum. Vaccines Immunother. 14, 839\u2013846 (2018).","journal-title":"Hum. Vaccines Immunother."},{"key":"1914_CR17","doi-asserted-by":"crossref","unstructured":"Mahalingam, D., et al. A phase II study of pelareorep (REOLYSIN((R))) in combination with gemcitabine for patients with advanced pancreatic adenocarcinoma. Cancers 10, 160 (2018).","DOI":"10.3390\/cancers10060160"},{"key":"1914_CR18","first-page":"215","volume":"19","author":"H Salmon","year":"2019","unstructured":"Salmon, H., Remark, R., Gnjatic, S. & Merad, M. Host tissue determinants of tumour immunity. Nat. Rev. Cancer 19, 215\u2013227 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"1914_CR19","doi-asserted-by":"publisher","first-page":"6286","DOI":"10.1128\/JVI.00205-12","volume":"86","author":"H Wang","year":"2012","unstructured":"Wang, H. et al. A new human DSG2-transgenic mouse model for studying the tropism and pathology of human adenoviruses. J. Virol. 86, 6286\u20136302 (2012).","journal-title":"J. Virol."},{"key":"1914_CR20","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1128\/JVI.80.7.3549-3558.2006","volume":"80","author":"C Jogler","year":"2006","unstructured":"Jogler, C. et al. Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species. J. Virol. 80, 3549\u20133558 (2006).","journal-title":"J. Virol."},{"key":"1914_CR21","doi-asserted-by":"publisher","first-page":"5957","DOI":"10.1158\/0008-5472.CAN-06-4309","volume":"67","author":"N Ahmed","year":"2007","unstructured":"Ahmed, N. et al. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 67, 5957\u20135964 (2007).","journal-title":"Cancer Res."},{"key":"1914_CR22","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24, 739\u2013748 (2018).","journal-title":"Nat. Med."},{"key":"1914_CR23","doi-asserted-by":"publisher","first-page":"6997","DOI":"10.1158\/0008-5472.CAN-11-1466","volume":"71","author":"M Hong","year":"2011","unstructured":"Hong, M. et al. Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res. 71, 6997\u20137009 (2011).","journal-title":"Cancer Res."},{"key":"1914_CR24","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-08-2281","volume":"69","author":"H Harlin","year":"2009","unstructured":"Harlin, H. et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 69, 3077\u20133085 (2009).","journal-title":"Cancer Res."},{"key":"1914_CR25","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.omtm.2019.11.001","volume":"15","author":"AR Shaw","year":"2019","unstructured":"Shaw, A. R. & Suzuki, M. Immunology of adenoviral vectors in cancer therapy. Mol. Ther. Methods Clin. Dev. 15, 418\u2013429 (2019).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1914_CR26","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.3389\/fimmu.2018.02103","volume":"9","author":"A Rosewell Shaw","year":"2018","unstructured":"Rosewell Shaw, A. & Suzuki, M. Oncolytic viruses partner with T-cell therapy for solid tumor treatment. Front. Immunol. 9, 2103 (2018).","journal-title":"Front. Immunol."},{"key":"1914_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-019-0721-x","volume":"12","author":"A Li","year":"2019","unstructured":"Li, A. et al. Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy. J. Hematol. Oncol. 12, 35 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"1914_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17011-z","volume":"11","author":"L Evgin","year":"2020","unstructured":"Evgin, L. et al. Oncolytic virus-derived type I interferon restricts CAR T cell therapy. Nat. Commun. 11, 3187 (2020).","journal-title":"Nat. Commun."},{"key":"1914_CR29","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/mt.2012.277","volume":"21","author":"M Suzuki","year":"2013","unstructured":"Suzuki, M. et al. Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo. Mol. Ther. 21, 796\u2013805 (2013).","journal-title":"Mol. Ther."},{"key":"1914_CR30","doi-asserted-by":"crossref","unstructured":"Xu, N., et al. STING agonist promotes CAR T cell trafficking and persistence in breast cancer. J. Exp. Med. 218, e20200844 (2021).","DOI":"10.1084\/jem.20200844"},{"key":"1914_CR31","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1089\/hum.2009.155","volume":"21","author":"M Suzuki","year":"2010","unstructured":"Suzuki, M. et al. MyD88-dependent silencing of transgene expression during the innate and adaptive immune response to helper-dependent adenovirus. Hum. Gene Ther. 21, 325\u2013336 (2010).","journal-title":"Hum. Gene Ther."},{"key":"1914_CR32","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","volume":"31","author":"S Spranger","year":"2017","unstructured":"Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31, 711\u2013723 e714 (2017).","journal-title":"Cancer Cell"},{"key":"1914_CR33","first-page":"7","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. CA 66, 7\u201330 (2016).","journal-title":"CA"},{"key":"1914_CR34","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.3389\/fimmu.2017.01176","volume":"8","author":"M Ma","year":"2017","unstructured":"Ma, M. et al. NKG2C(+)NKG2A(-) natural killer cells are associated with a lower viral set point and may predict disease progression in individuals with primary HIV infection. Front. Immunol. 8, 1176 (2017).","journal-title":"Front. Immunol."},{"key":"1914_CR35","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1002\/eji.200425843","volume":"35","author":"M Guma","year":"2005","unstructured":"Guma, M. et al. The CD94\/NKG2C killer lectin-like receptor constitutes an alternative activation pathway for a subset of CD8+ T cells. Eur. J. Immunol. 35, 2071\u20132080 (2005).","journal-title":"Eur. J. Immunol."},{"key":"1914_CR36","first-page":"304","volume":"8","author":"L Muller","year":"2017","unstructured":"Muller, L., Aigner, P., Stoiber, D. & Type, I. Interferons and natural killer cell regulation in cancer. Front. Immunol. 8, 304 (2017).","journal-title":"Front. Immunol."},{"key":"1914_CR37","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nm.3895","volume":"21","author":"MW Teng","year":"2015","unstructured":"Teng, M. W. et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat. Med. 21, 719\u2013729 (2015).","journal-title":"Nat. Med."},{"key":"1914_CR38","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.3389\/fimmu.2019.01242","volume":"10","author":"S Pesce","year":"2019","unstructured":"Pesce, S. et al. PD\/1-PD-Ls checkpoint: insight on the potential role of NK cells. Front. Immunol. 10, 1242 (2019).","journal-title":"Front. Immunol."},{"key":"1914_CR39","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cell.2020.03.001","volume":"181","author":"EW Weber","year":"2020","unstructured":"Weber, E. W., Maus, M. V. & Mackall, C. L. The emerging landscape of immune cell therapies. Cell 181, 46\u201362 (2020).","journal-title":"Cell"},{"key":"1914_CR40","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1136\/gutjnl-2018-316595","volume":"68","author":"D Raj","year":"2019","unstructured":"Raj, D. et al. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma. Gut 68, 1052\u20131064 (2019).","journal-title":"Gut"},{"key":"1914_CR41","doi-asserted-by":"publisher","first-page":"e1253656","DOI":"10.1080\/2162402X.2016.1253656","volume":"5","author":"N Watanabe","year":"2016","unstructured":"Watanabe, N. et al. Fine-tuning the CAR spacer improves T-cell potency. Oncoimmunology 5, e1253656 (2016).","journal-title":"Oncoimmunology"},{"key":"1914_CR42","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","volume":"12","author":"MH Kershaw","year":"2006","unstructured":"Kershaw, M. H. et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106\u20136115 (2006).","journal-title":"Clin. Cancer Res."},{"key":"1914_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0778-7","volume":"7","author":"P Metzger","year":"2019","unstructured":"Metzger, P. et al. Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer. J. Immunother. Cancer 7, 288 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1914_CR44","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1002\/jmv.25501","volume":"91","author":"L Kuryk","year":"2019","unstructured":"Kuryk, L., Moller, A. W. & Jaderberg, M. Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma. J. Med. Virol. 91, 1702\u20131706 (2019).","journal-title":"J. Med. Virol."},{"key":"1914_CR45","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1158\/1078-0432.CCR-18-1932","volume":"25","author":"HJ Chon","year":"2019","unstructured":"Chon, H. J. et al. Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune-checkpoint blockade. Clin. Cancer Res. 25, 1612\u20131623 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1914_CR46","doi-asserted-by":"publisher","first-page":"e1007209","DOI":"10.1371\/journal.ppat.1007209","volume":"14","author":"V Leoni","year":"2018","unstructured":"Leoni, V. et al. A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors. PLoS Pathog. 14, e1007209 (2018).","journal-title":"PLoS Pathog."},{"key":"1914_CR47","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka, R. H. et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J. Clin. Oncol. 33, 2780\u20132788 (2015).","journal-title":"J. Clin. Oncol."},{"key":"1914_CR48","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nri.2015.9","volume":"16","author":"A Cerwenka","year":"2016","unstructured":"Cerwenka, A. & Lanier, L. L. Natural killer cell memory in infection, inflammation and cancer. Nat. Rev. Immunol. 16, 112\u2013123 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"1914_CR49","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3389\/fimmu.2019.00496","volume":"10","author":"SA Lim","year":"2019","unstructured":"Lim, S. A. et al. Defective localization with impaired tumor cytotoxicity contributes to the immune escape of NK cells in pancreatic cancer patients. Front. Immunol. 10, 496 (2019).","journal-title":"Front. Immunol."},{"key":"1914_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-020-1177-8","volume":"20","author":"YP Tang","year":"2020","unstructured":"Tang, Y. P. et al. Prognostic value of peripheral blood natural killer cells in colorectal cancer. BMC Gastroenterol. 20, 31 (2020).","journal-title":"BMC Gastroenterol."},{"key":"1914_CR51","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1158\/2159-8290.CD-19-0620","volume":"10","author":"N Muthalagu","year":"2020","unstructured":"Muthalagu, N. et al. Repression of the type I interferon pathway underlies MYC- and KRAS-dependent evasion of NK and B cells in pancreatic ductal adenocarcinoma. Cancer Discov. 10, 872\u2013887 (2020).","journal-title":"Cancer Discov."},{"key":"1914_CR52","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/imm.12906","volume":"154","author":"JK Skelton","year":"2018","unstructured":"Skelton, J. K., Ortega-Prieto, A. M. & Dorner, M. A Hitchhiker\u2019s guide to humanized mice: new pathways to studying viral infections. Immunology 154, 50\u201361 (2018).","journal-title":"Immunology"},{"key":"1914_CR53","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1089\/hum.2009.096","volume":"21","author":"M Suzuki","year":"2010","unstructured":"Suzuki, M. et al. Large-scale production of high-quality helper-dependent adenoviral vectors using adherent cells in cell factories. Hum. Gene Ther. 21, 120\u2013126 (2010).","journal-title":"Hum. Gene Ther."},{"key":"1914_CR54","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1089\/hum.2012.003","volume":"23","author":"K Guse","year":"2012","unstructured":"Guse, K. et al. Capsid-modified adenoviral vectors for improved muscle-directed gene therapy. Hum. Gene Ther. 23, 1065\u20131070 (2012).","journal-title":"Hum. Gene Ther."},{"key":"1914_CR55","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1158\/2326-6066.CIR-18-0572","volume":"7","author":"R Parihar","year":"2019","unstructured":"Parihar, R. et al. NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors. Cancer Immunol. Res. 7, 363\u2013375 (2019).","journal-title":"Cancer Immunol. Res."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-021-01914-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-021-01914-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-021-01914-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T19:17:53Z","timestamp":1670095073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-021-01914-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1914"],"URL":"https:\/\/doi.org\/10.1038\/s42003-021-01914-8","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,19]]},"assertion":[{"value":"17 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.S. is a scientific consultant, and C.E.P is a consultant for Tessa Therapeutic Ltd. The other authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"368"}}